Regenerative therapy in cardiology by human amnion-derived immunotolerant cells in allogeneic combination

目前，对严重心力衰竭患者的确切治疗方法只有心脏移植。然而，缺乏捐献器官确实是一个世界性的社会问题。我们已经建立了羊膜间充质干细胞的分离系统，并显示了羊膜来源的细胞作为可移植生物材料的可用性。一旦从再生治疗的观点建立了可利用的细胞来源的细胞，必须解决细胞来源问题。在这项研究中，我们显示了长期的生存，在体内免疫耐受的细胞和阐明的机制。

At present, the definitive therapy to patients with severe heart failure is only heart transplantation. However, lack of donor organs is indeed a social problem in the world. We have previously established isolation system of mesenchymal stem cells from amnion, and showed availability of amnion-derived cells as a transplantable biomaterial. Once availability of amnion-derived cells from the viewpoint of regenerative therapy is established, cell source problem must be solved. In this study, we showed long-term survival of amnion-derived cells and elucidate mechanism of in vivo immune tolerance.